+91 9425150513 (Asia) support@24lifesciences.com
Regional Analysis, Demand Analysis and Competitive Outlook 2026-2033
MARKET INSIGHTS
Global Point-of-Care Infectious Disease Diagnostics & Testing market was valued at USD 2,027 million in 2024 and is projected to reach USD 2,786 million by 2031, exhibiting a CAGR of 4.8% during the forecast period.
Point-of-care (POC) infectious disease diagnostics involve rapid testing performed at or near the patient's location, delivering results typically within 15 minutes to enable immediate clinical decisions. These tests cover a wide range of applications including HIV, hepatitis B, respiratory infections (including COVID-19 and influenza), sexually transmitted infections, and tropical diseases. The technology encompasses lateral flow assays, molecular diagnostics, microfluidics, and biosensors.
The market growth is driven by increasing prevalence of infectious diseases, demand for decentralized testing, and technological advancements in diagnostic modalities. Recent innovations like Abbott's ID NOW rapid molecular testing platform and Roche's cobas Liat PCR system have significantly enhanced testing accuracy and speed. The COVID-19 pandemic has particularly accelerated adoption, with POC testing becoming crucial in outbreak management. Key challenges include regulatory hurdles and the need for continuous innovation to improve test sensitivity and specificity.
Growing Prevalence of Infectious Diseases
The increasing incidence of infectious diseases, including COVID-19, influenza, HIV, and hepatitis, is driving demand for rapid point-of-care diagnostics. Global healthcare systems prioritize immediate testing to contain outbreaks, with over 75% of clinical decisions relying on diagnostic results.
Advancements in Diagnostic Technologies
Innovations in molecular diagnostics, immunoassays, and microfluidics have enhanced the accuracy and speed of point-of-care testing. Portable devices now deliver lab-quality results in under 30 minutes, enabling timely clinical interventions.
➤ The global POC infectious disease testing market is projected to grow at 7.8% CAGR through 2028, fueled by pandemic preparedness initiatives.
Decentralization of healthcare services and growing adoption in resource-limited settings further propels market expansion, with emerging economies accounting for 40% of new device deployments.
MARKET CHALLENGES
Regulatory Hurdles and Quality Standards
Stringent regulatory approvals for POC diagnostics create barriers to market entry, with FDA/CE clearances often requiring extensive clinical validation. Maintaining consistent quality across decentralized testing locations remains an operational challenge.
Other Challenges
Reimbursement Limitations
Inadequate coverage policies for point-of-care testing constrain market growth, particularly in private healthcare systems where 65% of tests lack standardized payment structures.
Technical Complexities
Integrating multiplex detection capabilities while maintaining device simplicity challenges manufacturers, with false-positive rates still averaging 2-5% across rapid test formats.
High Development Costs
Substantial R&D investments required for novel POC technologies limit market participation, with average device development costs exceeding $15 million. This financial barrier restricts innovation primarily to established diagnostics companies.
Emerging Economies and Decentralized Care Models
Underserved regions present significant growth potential, with the WHO recommending expanded POC testing to bridge diagnostic gaps. Telemedicine integration creates additional opportunities, enabling remote test interpretation for 85% of common infectious diseases.
Multiplex Testing Platforms
Simultaneous detection of multiple pathogens addresses clinical needs for syndromic testing, with novel panels achieving 98% specificity for respiratory and tropical disease combinations.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Influenza/Flu POC remains the most clinically relevant segment due to seasonal outbreak patterns and ease of testing. HIV POC testing shows growing importance in resource-limited settings, while RSV diagnostics gain traction in pediatric care. Emerging infectious disease platforms demonstrate the highest innovation potential, with new assays continuously being developed. |
| By Application |
|
Hospitals dominate utilization due to their comprehensive diagnostic needs and emergency testing requirements. Clinics show growing adoption for decentralized testing models. Home care applications demonstrate the highest growth potential, driven by telehealth integration and patient convenience factors, though regulatory considerations remain challenging for this emerging segment. |
| By End User |
|
Healthcare Providers represent the most sophisticated user segment with complex testing needs and highest adoption of multiplex platforms. Diagnostic laboratories show sustained demand for confirmatory testing products, while home users demonstrate changing expectations for consumer-friendly infectious disease monitoring. Research institutions drive innovation in emerging pathogen detection technologies. |
| By Technology |
|
Molecular Diagnostics shows the most significant technological advancement, particularly in nucleic acid amplification techniques. Immunoassays maintain strong market presence due to reliability and lower costs. Microfluidics platforms gain adoption for their miniaturization advantages, while biosensor technologies demonstrate potential for continuous monitoring applications in high-risk settings. |
| By Pathogen Type |
|
Viral Pathogens dominate testing volumes due to their epidemic potential and rapid mutation rates. Bacterial testing maintains consistent demand, particularly for antibiotic resistance monitoring. Fungal and parasitic testing show specialized growth in immunocompromised patient populations. Emerging pathogen detection capabilities are becoming a key competitive differentiator among manufacturers. |
Innovation and Strategic Partnerships Drive Market Expansion
The Point-of-Care Infectious Disease Diagnostics & Testing market is dominated by multinational diagnostic giants, with Abbott and Roche holding significant market shares through their extensive product portfolios and global distribution networks. Abbott's BinaxNOW platform and Roche's cobas Liat system represent industry benchmarks in rapid infectious disease testing. The market exhibits an oligopolistic structure, with the top 5 players collectively controlling over 50% of global revenues, while specialized manufacturers focus on emerging infectious disease segments.
Innovative startups like Sight Diagnostics Ltd. and OJ-Bio Ltd. are gaining traction with AI-powered diagnostic solutions and novel biosensor technologies. Niche players such as Chembio Diagnostics and Trinity Biotech specialize in tropical disease tests, while established lab service providers like Quest Diagnostics expand their POC offerings through acquisitions. Regional players like Trivitron Healthcare are strengthening their position in emerging Asian markets through government partnerships.
List of Key Point-of-Care Infectious Disease Diagnostics & Testing Companies ProfiledRoche
Siemens Healthineers
BD & Company
Trinity Biotech
Cardinal Health
Quest Diagnostics Inc.
bioMérieux SA
Sight Diagnostics Ltd.
Gene POC
Trivitron Healthcare
Ortho-Clinical Diagnostics
The global Point-of-Care Infectious Disease Diagnostics & Testing market was valued at $2,027 million in 2024 and is projected to reach $2,786 million by 2031, growing at a CAGR of 4.8%. This growth is driven by increasing demand for rapid diagnostic solutions, particularly in resource-limited settings where traditional lab testing presents logistical challenges.
Other TrendsSegmentation by Disease Type
The market is segmented into HIV POC, Clostridium difficile POC, HBV POC, and respiratory infections testing (including RSV and Influenza POC). Respiratory infection testing currently holds the largest market share due to heightened surveillance post-COVID-19, with Influenza POC tests demonstrating 92-97% sensitivity in clinical validations.
Expanding Application Areas
Hospitals account for 42% of market applications, but home testing and assisted living facilities show the fastest growth (7.2% CAGR), reflecting the shift toward patient-centered care models.
Technological Advancements Driving Accuracy and EfficiencyRecent innovations include molecular POC platforms reducing test times from hours to 30 minutes while maintaining 98% accuracy comparable to central lab tests. Major players like Abbott and Roche are investing heavily in multiplex testing capabilities that can detect multiple pathogens from a single sample.
Regional Market Dynamics
North America leads with 38% market share, but Asia-Pacific shows the highest growth potential (6.1% CAGR), particularly in China and India where governments are expanding infectious disease screening programs. The European market is benefitting from increased healthcare budgets for antimicrobial resistance testing.
Regional Analysis: Point-of-Care Infectious Disease Diagnostics & Testing MarketEurope
Europe maintains strong position in point-of-care infectious disease testing, characterized by comprehensive national health systems integrating POC diagnostics into primary care pathways. The region shows particular strength in influenza, HIV, and tuberculosis testing at point-of-care, with notable adoption in UK, Germany, and Scandinavian countries. EU regulatory alignment through CE marking facilitates regional market entry, though country-specific reimbursement policies create variability in adoption rates. Increasing focus on antimicrobial resistance monitoring and implementation of POC testing in refugee health screening programs present new growth avenues. However, some Southern European markets face slower uptake due to budget constraints and preference for centralized laboratory testing models in public healthcare systems.
Asia-Pacific
Asia-Pacific emerges as the fastest growing region for POC infectious disease diagnostics, driven by massive unmet needs in rural healthcare access and increasing government spending on disease surveillance infrastructure. India and China lead adoption through national programs for HIV, hepatitis, and TB screening while Southeast Asian countries prioritize dengue and malaria rapid tests. Cultural acceptance of rapid diagnostics is high, though quality control remains inconsistent across some markets. Japanese healthcare system's focus on geriatric care and infection prevention in long-term facilities creates specialized demand. Telemedicine integration with POC results and emerging middle-class demand for instant testing in private clinics propel market expansion throughout the region.
Latin America
Latin America shows growing but uneven adoption of point-of-care infectious disease testing, with Brazil, Mexico, and Argentina as most advanced markets. Public health programs for HIV and syphilis testing during pregnancy drive volume while private sector adoption focuses on travel medicine and occupational health testing. Challenging geography in rural areas makes POC solutions vital but infrastructure limitations and regulatory fragmentation slow market maturation. Climate-sensitive diseases like dengue and Zika create seasonal demand spikes for rapid diagnostics. The region shows strong potential for locally manufactured POC tests but currently depends heavily on imports from North America and Europe.
Middle East & Africa
Middle East & Africa market remains in early growth stages, with Gulf countries showing most advanced POC adoption through hospital-based testing while Sub-Saharan Africa focuses on basic infectious disease screening in remote settings. HIV and malaria rapid tests dominate volume through international aid programs, though adoption remains supply-chain dependent. South Africa leads local capacity building while East African communities integrate POC testing with mobile health initiatives. Political instability in some regions disrupts consistent market growth, though pandemic preparedness investments are gradually expanding POC testing infrastructure across major urban centers.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Point-of-Care Infectious Disease Diagnostics & Testing market was valued at USD 2,027 million in 2024 and is projected to reach USD 2,786 million by 2031.
Which key companies operate in Global Point-of-Care Infectious Disease Diagnostics & Testing Market?
-> Key players include Abbott, Thermo Fisher Scientific Inc, Roche, Siemens Healthineers, and BD & Company, among others.
-> Key growth drivers include increasing prevalence of infectious diseases, demand for decentralized testing, and technological advancements in diagnostic modalities.
-> North America leads the market currently, while Asia-Pacific is expected to witness the fastest growth.
-> Emerging trends include molecular diagnostics, microfluidics, and rapid testing platforms for infectious diseases.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
